Skip to main content

Table 4 Survival analyses. LCtot - lung cancer total - lung cancer with and without COPD LCCOPD –lung cancer with COPD. LC –lung cancer with and without COPD

From: Levels and prognostic impact of circulating markers of inflammation, endothelial activation and extracellular matrix remodelling in patients with lung cancer and chronic obstructive pulmonary disease

  PFS OS PFS histology OS histology
Protein LC tot LC LCCOPD LC tot LC LCCOPD SQCC AC SQCC AC
OPG ns ns p = 0.01 HR = 0.17 [0.04–0.70] ns ns p = 0.03 HR = 0.14 [0.03–0.8] p = 0.02 HR = 0.19 [0.05–0.75] ns p = 0.03 HR = 0.16 [0.03–0.81] ns
PTX3 ns ns p = 0.01 HR = 1.70 [1.11–2.61] ns ns ns ns ns ns ns
vWF ns ns ns ns ns ns p = 0.05 HR = 3.14 [1.01–9.78] ns p = 0.01 HR = 7.68 [1.69–34.77] ns
ePCR ns ns ns ns p = 0.01 HR = 0.29 [0.11–0.77] ns ns ns ns ns
PARC p = 0.01 HR = 1.93 [1.16–3.22] ns ns ns ns ns ns ns ns ns
Cats ns ns ns ns ns ns ns ns ns p = 0.01 HR = 39.44 [2.27–684.2]
sTNFR1 p = 0.03 HR = 0.57 [0.35–0.94] ns p = 0.03 HR = 0.49 [0.25–0.93] p = 0.01 HR = 0.45 [0.25–0.83] p = 0.04 HR = 0.3 [0.09–0.95] p = 0.01 HR = 0.33 [0.15–0.73] ns p = 0.01 HR = 0.37 [0.18–0.78] p = 0.02 HR = 0.31 [0.11–0.85] p = 0.001 HR = 0.24 [0.10–0.58]
CRP ns ns ns p = 0.002 HR = 1.41 [1.13–1.75] p = 0.01 HR = 1.73 [1.14–2.63] p = 0.17 HR = 1.59 [1.09–2.33] ns p = 0.03 HR = 1.39 [1.04–1.85] p = 0.02 HR = 1.61 [1.08–2.40] p = 0.01 HR = 1.6 [1.11–2.34]
  1. Legends: Multivariate Cox regression analyses were conducted for the whole lung cancer group, and for subgroups including lung cancer with COPD, lung cancer without COPD, squamous cell carcinomas and adenocarcinomas
  2. We adjusted for explanatory variables like packyear, histology, gender, age, and stage
  3. OS overall survival, PFS progression free survival, HR [] Hazard Ratio with 95% confident interval